Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
← catalyst calendarNCT07311993 · readout ≤ 559 d
Sponsored by Cellectar Biosciences, Inc. (industry) · CLRB — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
60estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-05 | actual | When the study began enrolling |
| Primary completion | Feb 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Breast Cancer
Interventions
- Drug: Iopofosine I 131 — also filed as CLR 131
- Drug: CLR 125
Primary outcomes
what the primary-completion date above is the date OFDose Determination for CLR 125
measured 57 days after initiation of last cycle (each cycle is 57 days)
Number of adverse events related to study treatment (CLR 125)
measured Assessed throughout the study through 1 year following completion of treatment.
Permalink · CLRB's whole pipeline · Catalyst calendar · Every registered study · What changed